Literature DB >> 19770444

Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome.

Yusuke Asano1, Hiroaki Kagawa, Yoko Kano, Tetsuo Shiohara.   

Abstract

BACKGROUND: Overt cytomegalovirus (CMV) disease is a serious viral infection that usually occurs in immunocompromised patients but rarely in immunocompetent patients. Cutaneous lesions, albeit rare, occur as late systemic manifestations of CMV infections and are usually fatal. OBSERVATIONS: We describe 2 patients with drug-induced hypersensitivity syndrome (one end of a spectrum of severe drug eruptions) who subsequently developed cutaneous CMV ulcers at unusual sites, such as the trunk; this occurrence was immediately followed by gastrointestinal manifestations, which were fatal in 1 patient. To identify factors predictive of CMV disease, we retrospectively investigated the prevalence of CMV reactivation during drug-induced hypersensitivity syndrome in 18 patients. In this analysis, patients were divided into 2 groups depending on the positivity of CMV DNA in the blood.
CONCLUSIONS: Older and male patients with antecedent high human herpesvirus 6 DNA loads are at risk for CMV disease irrespective of corticosteroid administration. A rapid reduction in white blood cell numbers is also predictive of the onset of CMV disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19770444     DOI: 10.1001/archdermatol.2009.195

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  13 in total

1.  Cytomegalovirus (CMV) hepatitis: an uncommon complication of CMV reactivation in drug reaction with eosinophilia and systemic symptoms.

Authors:  Yu Jun Wong; Karen Jui Lin Choo; Jade Xiao Jue Soh; Chee Kiat Tan
Journal:  Singapore Med J       Date:  2018-02       Impact factor: 1.858

Review 2.  Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review.

Authors:  Ivan Gentile; Maria Talamo; Guglielmo Borgia
Journal:  BMC Infect Dis       Date:  2010-03-06       Impact factor: 3.090

3.  Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

Authors:  Natsumi Hama; Riichiro Abe; Andrew Gibson; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-15

4.  Update on the management of antibiotic allergy.

Authors:  Bernard Yu-Hor Thong
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

5.  Detection of cytomegalovirus in the gastric ulcer of a patient with drug-induced hypersensitivity syndrome.

Authors:  Ko Kagoyama; Teruhiko Makino; Chieko Ueda; Yoshiaki Takegami; Tadamichi Shimizu
Journal:  JAAD Case Rep       Date:  2015-06-17

Review 6.  New Insights into Drug Reaction with Eosinophilia and Systemic Symptoms Pathophysiology.

Authors:  Philippe Musette; Baptiste Janela
Journal:  Front Med (Lausanne)       Date:  2017-12-04

Review 7.  Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions.

Authors:  Mari Orime
Journal:  J Immunol Res       Date:  2017-10-31       Impact factor: 4.818

Review 8.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

Review 9.  Crucial Role of Viral Reactivation in the Development of Severe Drug Eruptions: a Comprehensive Review.

Authors:  Tetsuo Shiohara; Yukiko Ushigome; Yoko Kano; Ryo Takahashi
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 10.817

10.  The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome.

Authors:  T Ishida; Y Kano; Y Mizukawa; T Shiohara
Journal:  Allergy       Date:  2014-04-17       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.